Cullinan Therapeutics Inc (CGEM)

Stifel has adjusted their stance on Cullinan Therapeutics ( $CGEM ), setting the rating to Buy with a target price of 23 → 19.

$CGEM girl at the bar said hop out this so ok

$CGEM in at $7.68 Or… Stop loss at $7 #FallingKnife

$CGEM looking for 7.75 - 8 range before getting back in

Stifel has updated their rating for Cullinan Therapeutics ( $CGEM ) to Buy with a price target of 22.

Looks like $CGEM chart is climbing due to the potential in T Cell bispecific antibody technology for Acute Myeloid Leukemia. With a primary completion date estimate in August 2025 and study completion date estimate of November 2025. They just licensed $20 million in exclusive rights for a BCMA bispecific T Cell engager. With milestone payments up to $692 Million. Cullinan has cash resources into 2028. Currently at $8.64 from $7.21 during May 2025.

$CGEM https://prismmarketview.com/cullinan-adds-potential-best-in-class-bcma-t-cell-engager-for-autoimmune-diseases-shares-global-rights-outside-greater-china/

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix $CGEM https://stocktwits.com/news/equity/markets/cullinan-therapeutics-stock-slides-after-hours-despite-692-m-autoimmune-drug-pact-with-genrix/chkDeRoRbDh

$CGEM Cullinan licenses rights to velinotamig from Genrix Bio for $20M upfront Cullinan Therapeutics announced that it has entered into an agreement with Genrix Bio for a global, all indication, exclusive license to velinotamig, a BCMAxCD3 bispecific T cell engager. Velinotamig has demonstrated potential efficacy at the Phase 2 target dose in nearly 50 patients with relapsed/refractory multiple myeloma. Cullinan will develop velinotamig in autoimmune diseases. Genrix plans to initiate a Phase 1 study in China by the end of this year in patients with autoimmune diseases. Cullinan intends to use the data generated to accelerate global clinical development of the program. Following the completion of the Genrix Bio Phase 1 study, Cullinan will conduct all further development of velinotamig in autoimmune diseases. Under the agreement, Cullinan will pay Genrix Bio an upfront license fee of $20M for exclusive rights to develop and commercialize velinotamig in all disease areas globally outside of Greater China. In the future, Genrix will also be eligible to receive up to $292M in development and regulatory milestones plus up to an additional $400M in sales-based milestones, as well as tiered royalties from mid-single digits up to the mid- teens on potential ex-Greater China net sales. Importantly, with refinement of the clinical oncology pipeline, Cullinan reiterates its existing guidance to have cash resources into 2028 based on its current operating plan.

$CGEM great news for zipalertinib. https://www.fiercebiotech.com/biotech/asco-cullinan-and-taiho-unveil-nsclc-data-behind-fda-application-plans

$CGEM Cullinan Therapeutics to present new results from REZILIENT1 trial Cullinan Therapeutics, Taiho Pharmaceutical and Taiho Oncology announced new results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations who have received prior therapy. These data will be presented on Sunday, June 1 at the American Society of Clinical Oncology annual meeting as an oral presentation. As of the December 2024 data cutoff, 244 patients were enrolled in REZILIENT1 and received at least one dose of 100 mg zipalertinib. The overall efficacy population consisted of all patients who received at least one dose of 100 mg zipalertinib and had approximately 8 months of minimum follow-up at data cutoff. Patients had received a median of 2 prior therapies, and 39% of patients had a history of brain metastases. With median follow-up of 9.3 months, zipalertinib demonstrated: In the overall efficacy population, confirmed overall objective response rate was 35% with median duration of response of 8.8 months; in patients with prior platinum-based chemotherapy only, ORR was 40% with mDOR of 8.8 months, consistent with REZILIENT1 Phase 1/2a results; in patients with prior chemo and amivantamab, ORR was 30% with mDOR of 14.7 months; in patients with prior chemo and amivantamab, ORR was 24% with mDOR of 8.5 months and in patients with brain metastases, the ORR was 31% with mDOR of 8.3 months. The safety analysis population included all REZILIENT1 patients who received at least one dose of 100 mg zipalertinib. The results showed that zipalertinib demonstrated a manageable safety profile in this heavily pre-treated patient population, consistent with previously reported data. The most common treatment-related adverse events were paronychia, rash, dermatitis acneiform, dry skin, diarrhea and stomatitis. The majority of TRAEs were grade 1 or 2. The most common grade 3 TRAEs were anemia, pneumonitis and rash, increased alanine aminotransferase, diarrhea, and decreased platelet count.

UBS has adjusted their stance on Cullinan Therapeutics ( $CGEM ), setting the rating to Buy with a target price of 30 → 24.

$CGEM why is this getting hammered.. no relation with V Prasad and upcoming data at ASCO and anti-MICA data... Valuation based on CLN-978 a novel, highly potent CD19xCD3 bispecific T cell engager and cash position 600mil$

$CGEM CYDY

$CGEM promise mainly within zipalertinib for exon 20 mutations NSCLC. Company should focus on getting this to the finish line.

watch now $CGEM, $EYPT and $NTLA

HC Wainwright & Co. updates rating for Cullinan Therapeutics ( $CGEM ) to Buy, target set at 33.

$CGEM Cullinan Therapeutics Receives Approval From European Medicines Agency To Initiate Phase 1 Trial of CLN-978 In Patients With Rheumatoid Arthritis

$CGEM 📈🚀📈🚀

Morgan Stanley updates rating for Cullinan Therapeutics ( $CGEM ) to Overweight, target set at 38 → 35.

$CGEM At least other bioturds goes down with a clear reason, this shit just goes down

HC Wainwright & Co. has adjusted their stance on Cullinan Therapeutics ( $CGEM ), setting the rating to Buy with a target price of 33.